jump over navigation bar
NIH Consensus Development Program Homepage
jump over navigation barHome Page for the NIH Consensus Development ProgramAbout the NIH Consensus Development Program Previous Conference Statements from the NIH Consensus Development ProgramFAQs on the NIH Consensus Development Program

 
""Upcoming Conferences in 2010


Please save the date for the following conferences scheduled for 2010:

Enhancing Use and Quality of Colorectal Cancer Screening
Lactose Intolerance and Health
Vaginal Birth After Cesarean: New Insights
Preventing Alzheimer’s Disease and Cognitive Decline
 

Registration will be open six to nine months prior to each conference and additional information will be available at that time.  Please note that all conferences are free and open to the public.


If you would like to be notified when registration opens and when the statement is available, please sign up for alerts at http://consensus.nih.gov/alerts.htm.

 

NIH State-of-the-Science Conference:
Enhancing Use and Quality of Colorectal Cancer Screening
February 2–4, 2010
Bethesda, Maryland

 

The Panel will address the following questions:

  • What are the recent trends in the use and quality of colorectal cancer screening?

  • What factors influence the use of colorectal cancer screening?

  • Which strategies are effective in increasing the appropriate use of colorectal cancer screening and followup?

  • What are the current and projected capacities to deliver colorectal cancer screening and surveillance at the population level?

  • What are the effective approaches for monitoring the use and quality of colorectal cancer screening?

  • What research is needed to make the most progress and have the greatest public health impact in promoting the appropriate use of colorectal cancer screening?

 

NIH Consensus Development Conference:

Lactose Intolerance and Health

February 22-24, 2010
Bethesda, Maryland

 

The Panel will address the following questions:

  • What is the prevalence of lactose intolerance, and how does this prevalence differ by race, ethnicity, and age?

  • What are the health outcomes of dairy exclusion diets?

  • What amount of daily lactose intake is tolerable in subjects with diagnosed lactose intolerance?

  • What strategies are effective in managing individuals with diagnosed lactose intolerance?

  • What are the future research needs for understanding and managing lactose intolerance?

 

NIH Consensus Development Conference:

Vaginal Birth After Cesarean: New Insights
March 8–10, 2010
Bethesda, Maryland

 

The Panel will address the following questions:

  • What are the rates and patterns of utilization of trial of labor after prior cesarean, vaginal birth after cesarean, and repeat cesarean delivery in the United States?

  • What are the nonmedical factors that influence the patterns and utilization of trial of labor after prior cesarean?

  • Among women who attempt a trial of labor after prior cesarean, what is the vaginal delivery rate and the factors that influence it?

  • What are the short- and long-term benefits and harms to the mother of attempting trial of labor after prior cesarean versus elective repeat cesarean delivery, and what factors influence benefits and harms?

  •  What are the short- and long-term benefits and harms to the baby of maternal attempt at trial of labor after prior cesarean versus elective repeat cesarean delivery, and what factors influence benefits and harms?

  • What are the critical gaps in the evidence for decisionmaking, and what are the priority investigations needed to address these gaps?

 

NIH State-of-the-Science Conference:

Preventing Alzheimer’s Disease and Cognitive Decline
April 26–28, 2010
Bethesda, Maryland

 

The Panel will address the following questions:

  • What factors are associated with the reduction of risk of Alzheimer’s disease?

  • What factors are associated with the reduction of risk of cognitive decline in older adults?

  • What are the relationships between the factors that affect Alzheimer’s Disease and the factors that affect cognitive decline?

  • What are the therapeutic and adverse effects of interventions to delay the onset of Alzheimer’s Disease?

  • What are the therapeutic and adverse effects of interventions to improve or maintain cognitive ability, or preserve cognitive function? Are there outcomes in identifiable subgroups?

  • If recommendations for interventions cannot be made currently, what studies need to be done that could provide the quality and strength of evidence necessary to make such recommendations to individuals?

 
 

 

 

 


 







 

 

 

 

 

 

 




 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 




 


 
 

Contact Consensus Program | Privacy Notice | Disclaimer | Accessibility | Contact NIH
Department of Health and Human Services HomepageNational Institutes of Health Home PageFirstGov Home Page - The U.S. Government's Official Web Portal  National Guideline ClearingHouse - a public resource for evidence-based clinical practice guidelines